Trial
NCT06399679
Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium
Phase IISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
American Academy of Clinical Toxicology
Condition
Anticholinergic Toxicity
Intervention
Rivastigmine
Why stopped
Physostigmine (standard of care treatment under this protocol) became unavailable at the study site June 1st 2026, requiring suspension of the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-04